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Abstract
Purpose:  To  evaluate  the  safety  and  efﬁcacy  of  a  new  multipurpose  disinfecting  solution  (MPDS)
with a  formulation  that  includes  aloe  vera  on  its  composition.
Methods:  This  is  a  prospective,  randomized,  double-masked  clinical  trial  with  a  crossover  design
that included  seven  examinations.  Two  different  MPDSs,  Avizor  Alvera®  (study  solution)  and  All
Clean Soft®  (control  solution),  each  were  used  for  1  month.  Comﬁlcon  A  silicone  hydrogel
contact lenses  were  used  during  the  trial.  The  main  outcome  variables  were  corneal  staining
and deposits  on  the  surfaces  of  the  contact  lenses.  Other  parameters  including  ocular  surface
response, contact  lens  wettability,  user  satisfaction,  and  adverse  events,  were  analyzed  accord-
ing to  the  International  Organization  for  Standardization  (ISO)  11980:2010  guidance  for  clinical
investigation.
Results:  Twenty  subjects  (10  women,  10  men)  (mean  age,  27.7  ±  5.6  years;  range,  20--41)  were
included.  No  differences  between  both  MPDSs  were  found  in  the  percentage  of  subjects  with
corneal staining  >0  at  day  30  (study:  35%,  control:  50%;  p  =  0.46);  neither  in  the  percentage  of
subjects with  deposits  on  the  surface  of  the  contact  lens  >0  at  day  30  (study:  26.32%,  control:
52.63%; p  =  0.18).  The  study  MPDS  received  higher  rates  in  comfort  (study:  8.14  ±  1.09,  con-
trol: 7.94  ±  0.92;  p  =  0.56)  and  satisfaction  at  day  30  (study:  8.63  ±  0.91,  control:  8.29  ±  0.80;
p =  0.19),  however  the  scores  were  not  signiﬁcantly  different  with  the  control  MPDS.
Conclusions:  The  clinical  trial  showed  that  the  study  MPDS  is  safe,  efﬁcient,  and  has  acceptable
physiologic  tolerance,  according  to  the  ISO  11980:2010  guidance  for  clinical  investigation.
© 2014  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.
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PALABRAS  CLAVE
Lentes  de  contacto;
Solución  de  múltiples
objetivos
Evaluación  de  la  seguridad  y  eﬁcacia  de  una  nueva  solución  multipropósito  en  lentes
de  contacto  de  hidrogel  de  silicona
Resumen
Objetivo:  Evaluar  la  seguridad  y  la  eﬁcacia  de  una  nueva  solución  única  desinfectante  (MPDS),
con una  formulación  que  incluye  aloe  vera  en  su  composición.
Métodos:  El  estudio  consistió  en  un  ensayo  clínico  prospectivo,  aleatorio  y  de  doble  ciego,
con un  disen˜o  cruzado  que  incluyó  siete  exámenes.  Se  utilizaron  durante  un  mes  dos  MPDS
diferentes, Avizor  Alvera®  (solución  en  estudio)  y  All  Clean  Soft®  (solución  de  control).  Durante
el ensayo  se  utilizaron  lentes  de  contacto  de  hidrogel  de  silicona  Comﬁlcon  A.  Las  principales
variables evaluadas  fueron  la  tinción  corneal  y  los  depósitos  sobre  la  superﬁcie  de  las  lentes  de
contacto. Se  analizaron  otros  parámetros,  que  incluían  la  respuesta  de  la  superﬁcie  ocular,  la
humectabilidad  de  las  lentes  de  contacto,  y  los  eventos  adversos,  de  acuerdo  con  la  normativa
11980:2010  de  la  Organización  Internacional  de  Normalización  (ISO)  para  investigación  clínica.
Resultados:  El  estudio  incluyó  a  veinte  sujetos  (10  mujeres,  10  hombres)  (edad  media,
27,7 ±  5,6  an˜os;  rango,  20-41).  No  se  hallaron  diferencias  entre  ambas  MPDS  en  cuanto  al
porcentaje  de  sujetos  con  tinción  corneal  >  0  al  mes  (estudio:  35%,  control:  50%;  p  =  0,46),
ni el  porcentaje  de  sujetos  con  depósitos  en  la  superﬁcie  de  las  lentes  de  contacto  >  0  al  mes
(estudio: 26,32%,  control:  52,63%;  p  =  0,18).  La  MPDS  en  estudio  obtuvo  valoraciones  super-
iores en  cuanto  a  confort  (estudio:  8,14  ±  1,09,  control:  7,94  ±  0,92;  p  =  0,56)  y  satisfacción
(estudio: 8,63  ±  0,91,  control:  8,29  ±  0,80;  p  =  0,19);  sin  embargo,  las  puntuaciones  no  fueron
signiﬁcativamente  diferentes  en  relación  a  la  MPDS  de  control.
Conclusiones:  El  ensayo  clínico  reﬂejó  que  la  MPDS  en  estudio  es  segura  y  eﬁcaz,  mostrando  una
tolerancia  ﬁsiológica  aceptable,  de  acuerdo  con  la  normativa  ISO  11980:2010  para  investigación
clínica.
© 2014  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  España,  S.L.U.  Todos  los
derechos reservados.
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IIntroduction
About  76%  of  contact  lens  (CL)  users  clean  and  disinfect
their  CLs  with  chemical  care  systems,  including  multipur-
pose  disinfecting  solutions  (MPDSs).1 For  that  reason,  the
MPDS  formulas  include  an  antimicrobial  agent,  a  buffer  sys-
tem,  and  in  some  cases  a  surfactant  agent.2 However,  MPDSs
can  interfere  with  the  integrity  and  function  of  the  corneal
epithelium  which  may  cause  clinically  relevant  signs  and
symptoms  of  discomfort  with  the  CLs.  Although  surfactant
agents  also  can  cause  irritation,  antimicrobial  or  preserving
agents  are  the  most  decisive  factors  that  produce  ocular
surface  irritation.3,4
The  use  of  preserving  and/or  disinfectant  agents  in  solu-
tions  that  come  into  contact  with  the  eyes  (MPDS,  lubricant
drops,  eyedrops)  is  not  risk-free,  particularly  regarding  the
corneo-conjunctival  surface,  because  their  toxicity  may
affect  the  ocular  surface  cells.  A  study  of  several  MPDSs
that  included  different  types  of  antimicrobial  agents  in  their
formulations  reported  abnormal  exfoliation  of  the  corneal
epithelial  layers.5
A  new  MPDS  (Avizor  Alvera®  MPDS,  Avizor  S.A.,  Madrid,
Spain)  has  been  developed  with  a  speciﬁc  formulation  that
incorporates  aloe  vera,  which  protects  the  ocular  surface
epithelium.6 Aloe  vera  is  a  natural  source  of  mannose-6-
phosphate  (M6P),7 this  natural  complex  sugar  can  inactivate
the  action  of  certain  inﬂammatory  mediators  by  a  compet-
itive  blocking  of  certain  keratocytes  receptors  from  which
these  mediators  exert  their  action.8 Considering  the  neg-
ative  effect  of  the  antimicrobial  agent  in  MPDSs  on  the
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+orneal  surface,  it  is  of  interest  to  identify  an  agent  that  pre-
ents  irritation  caused  by  preserving  and  surfactant  agents
hat  can  be  incorporated  into  MPDSs  without  interfering  with
he  cleaning  and  disinfecting  processes  of  the  MPDS.
The  purpose  of  the  current  study  was  to  determine  the
afety  and  efﬁcacy  of  the  Avizor  Alvera  MPDS  compared  with
 control  MPDS,  All  Clean  Soft  (Avizor  S.A.)  as  a  MPDS  used  to
lean  and  disinfect  silicone  hydrogel  CLs  (Si-HCLs)  for  over
 month.
ethods
esign
he  current  study  was  a  prospective,  randomized,  double-
asked,  crossover  clinical  trial  with  seven  scheduled
xaminations.  Fig.  1  shows  a  ﬂow  chart  of  the  study  for  a  bet-
er  understanding  of  the  design.  The  Valladolid  Este  Ethics
ommittee,  Valladolid,  Spain,  and  the  Spanish  National
ealth  Authority  (Spanish  Drugs  and  Health  Products  Agency,
egistration  number  2011-000604-18)  approved  the  study.
ll  subjects  were  treated  according  to  the  Declaration  of
elsinki.
nclusion/exclusion  criteriahe  study  included  20  hydrogel  CLs  wearers  over  18  years
f  age  with  refraction  between  −10.00  diopters  (D)  and
8.00  D,  astigmatism  less  than  2.25  D,  and  a  minimum  of
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Selection failure
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fFigure  1  Stud
 year  of  habitual  CL  wear  (at  least  5  days  weekly  for  at
east  5  h  daily).  Both  eyes  were  examined,  but  only  data
rom  one  eye  was  chosen  randomly  for  analysis.  Subjects
ere  excluded  if  they  had  an  active  ocular  surface  disease
r  a  systemic  disease  that  could  affect  ocular  physiology  or
orsen  with  CL  wear.  The  exclusion  criteria  included  intol-
rance  or  sensitivity  to  the  study  products,  ocular  infection
r  a  history  of  herpetic  keratitis,  severe  inﬂammation  during
he  6  months  before  the  study,  use  of  an  ocular  topical  med-
cation  in  the  previous  3  months  (except  artiﬁcial  tears)  or
 systemic  medication  that  could  possibly  affect  the  tear
lm,  refractive  surgery,  corneal  irregularities,  pregnancy
nd  breastfeeding,  corneal  edema,  corneal  neovascularisa-
ion  or  inﬁltrates  graded  1  or  higher,  tarsal  or  conjunctival
yperemia  graded  2  or  higher,  ﬂuorescein  corneal  staining
raded  2  or  higher  in  any  area,  the  sum  of  all  the  areas
raded  4  or  higher,  or  greater  than  20%  staining.9Ls  and  solutions
our  pairs  of  silicone  Si-HCLs  (BioﬁnityTM and  Bioﬁnity
oricTM,  Comﬁlcon  A,  Cooper  Vision  Inc.,  Fairport,  NY,  USA,
i
H
h
Ssign  ﬂowchart.
ase  curve:  8.60  mm,  diameter:  14.00  mm,  power  range
rom  +8.00  to  −10.00,  and  cylinder  up  to  2.25  D)  were  dis-
ensed  to  each  subject  during  the  trial:  two  pairs  for  the
wo  washout  periods  (1  week  each),  and  two  pairs  for  the
tudy  or  control  solution  periods  (30  days  each).  Subjects
ere  instructed  not  to  sleep  or  nap  while  wearing  the  CLs
uring  the  study  and  to  wear  the  provided  CLs  a  minimum
f  5  h  daily  and  5  days  weekly  during  the  study.
The  study  (Avizor  Alvera,  Avizor  S.A.)  and  control  (All
lean  Soft,  Avizor  S.A.)  solutions  were  randomly  assigned.
he  use  of  the  MPDS  was  randomized  and  double-masked
uring  the  study.  Both  solutions  were  masked  by  the  man-
facturer.  The  packaging  of  both  solutions  was  identical.
 5-digit  code  was  randomly  assigned  to  each  bottle.  Two
odes  were  assigned  to  each  subject,  one  corresponding  to
he  control  solution  and  other  one  to  the  study  solution.  The
olutions  delivery  and  the  evaluation  of  subjects  were  per-
ormed  by  different  evaluators.  Patients  received  written
nstructions  regarding  the  use  and  maintenance  of  their  Si-
CLs.  The  composition  of  both  MPDSs  is  shown  in  Table  1.  A
ydrogen  peroxide  system  was  provided  (Ever  Clean,  Avizor
.A.)  for  washout  periods.
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Table  1  Composition  of  the  multipurpose  disinfecting  solutions  used  in  the  study.
Brand  Components  Other
Buffer  Preservative  Surfactant
Avizor  Alvera  Borax/boric  acid  EDTA,  polyhexanide  0.0002%  Poloxamer  Polyvinylpyrrolidone  aloe  vera
All Clean  Soft  Borax/boric  acid  EDTA,  polyhexanide  0.0002%  Poloxamer
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sEver Clean  Hydrogen  peroxide  3%  
Study  schedule
All  subjects  completed  seven  examinations  with  two
washout  periods.  The  study  design  followed  the  require-
ments  of  the  International  Organization  for  Standardization
(ISO)  11980:2010  guidance  for  clinical  investigation  (Oph-
thalmic  optics,  CL,  and  CL  care  products).9
Baseline  examination
The  subjects  attended  this  examination  without  wearing  CLs
for  at  least  24  h.  The  clinical  trial  procedures  were  explained
to  the  subjects,  and  each  subject  provided  informed  consent
and  signed  a  data  protection  form.
Medical  and  CL  histories  were  obtained  and  the  subjects
underwent  an  ocular  examination.  Subjective  refraction  and
LogMAR  visual  acuity  (LogMAR  VA)  with  an  ETDRS  chart  was
measured;  keratometry  and  slit-lamp  evaluation  of  the  ocu-
lar  surface  were  performed  to  determine  if  they  met  the
inclusion  and  exclusion  criteria.  Women  of  childbearing  age
who  wished  to  participate  in  the  study  should  perform  a
pregnancy  test.  All  subjects  who  complied  with  the  inclusion
and  exclusion  criteria  were  scheduled  for  the  next  examina-
tion  within  the  following  10  days  after  baseline  examination.
Examination  1
Subjects  attended  the  examination  without  wearing  CLs  for
at  least  24  h.  Changes  in  health  status  or  medication  and  pos-
sible  adverse  events  since  the  previous  examination  were
scored;  if  the  medication  change  might  affect  the  ocular
surface  the  patient  discontinued  the  study.  A  new  Si-HCL
with  the  subjects  parameters  was  inserted,  and  after  waiting
30  min  the  following  procedures  were  performed:  measure-
ment  of  the  LogMAR  VA,  assessment  of  the  Si-HCL  ﬁt  (corneal
coverage,  position,  and  mobility),  and  evaluation  of  lim-
bal  and  bulbar  hyperemia.  The  subjects  wore  this  Si-HCL
for  1  week  during  the  ﬁrst  washout  period  and  received
a  hydrogen  peroxide  system  (Ever  Clean)  for  cleaning  and
maintaining  the  Si-HCLs.
Examination  2
This  examination  was  7  ±  1  days  after  examination  1.  The
subjects  attended  the  clinic  after  having  worn  the  Si-HCLs
for  at  least  5  h.  Changes  in  health  status  or  medication
and  possible  adverse  events  since  the  previous  examination
were  scored.  Biomicroscopy  signs  evaluated  were  bulbar  and
limbal  hyperemia,  presence  of  papillae  and  follicles,  epithe-
lial  and  stromal  edema,  corneal  inﬁltrates,  endothelial
v
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egularity,  corneal  vascularization,  anterior  segment  inﬂam-
ation  and  bulbar  and  corneal  staining.  After  the  eyes  were
insed,  a  new  pair  of  Si-HCLs  was  inserted  and  after  60  min,
he  LogMAR  VA,  CL  ﬁt,  bulbar  and  limbal  hyperemia,  and
eposits  on  the  anterior  and  posterior  CL  surfaces  were  eval-
ated.  This  pair  of  Si-HCL  was  worn  for  30  days  (at  least  5  h
aily  and  5  days  weekly)  using  the  assigned  MPDS  solution
study  or  control,  randomly  assigned)  according  to  the  oral
nd  written  instructions  provided.
xamination  3
his  examination  was  15  ±  2  days  after  examination  2.  At
his  visit  the  same  procedure  as  in  the  previous  visit  was  fol-
owed.  Tests  performed  at  this  visit  were:  subject  comfort
nd  satisfaction,  LogMAR  VA,  non-invasive  break-up  time
NIBUT),  CL  ﬁt  and  grade  of  deposits  and  biomicroscopy
igns.
xamination  4
his  examination  was  30  ±  2  days  after  examination  3.  The
ame  process  as  examination  3  was  performed.  The  Si-HCLs
nd  MPDSs  for  this  part  of  the  trial  were  collected,  and  a  new
air  of  Si-HCLs  was  inserted.  After  30  min  the  LogMAR  VA,  SI-
CL  ﬁt,  and  bulbar  and  limbal  hyperemia  were  evaluated.
his  pair  of  lenses  was  worn  for  1  week,  corresponding  to
he  second  washout  period.  The  care  solution  for  this  phase
as  the  same  hydrogen  peroxide  system  used  in  the  ﬁrst
ashout  period  between  examinations  1  and  2.
xaminations  5,  6,  and  7
he  same  procedures  and  same  schedule  were  followed  as
or  examinations  2,  3,  and  4,  respectively.  The  subjects
eceived  the  second  randomized  study  or  control  solution.
linical  measurements
he  main  safety  variable  was  deﬁned  as  the  percentage  of
ubjects  without  corneal  ﬂuorescein  staining  or  a  maximum
f  grade  1  staining  at  the  end  of  the  month  using  the  study
PDS  versus  the  control  MPDS.
To  assess  the  corneal  ﬂuorescein  staining,  5  l  of  2%
odium  ﬂuorescein  were  instilled  in  the  lower  conjuncti-
al  cul-de-sac  with  a  micropipette  (Finnpipette®  0.5--10  l;
antaa,  Finland).  Two  minutes  later,  the  anterior  corneal
urface  was  examined  by  slit-lamp  with  a  16×  magniﬁcation
ens  and  the  cobalt  blue  ﬁlter  and  through  a  Wratten  #12
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ellow  ﬁlter.  The  cornea  was  evaluated  using  a  grid  with  ﬁve
reas  (central,  temporal,  nasal,  superior,  and  inferior).  The
ntensity  of  the  corneal  ﬂuorescein  staining  was  evaluated
n  each  area  and  scored  on  a  scale  from  0  to  4.9
The  main  efﬁcacy  variable  was  deﬁned  as  the  difference
n  the  percentage  of  subjects  without  deposits  on  the  ante-
ior  or  posterior  CL  surfaces  or  maximum  of  grade  2  at  the
nd  of  the  month  using  the  study  MPDS  versus  the  control
PDS.  Deposits  were  evaluated  by  slit-lamp  with  20×  mag-
iﬁcation  and  white  light,  evaluating  the  CL  anterior  and
osterior  surfaces  while  the  CL  was  on  the  eye,  and  the
eposits  were  graded  on  a  scale  of  0--4.9
Secondary  variables  evaluated  were:  subject  comfort  and
atisfaction,  CL  anterior  surface  wettability  (NIBUT),  lens
tting  characteristics,  and  ocular  surface  health  status  eval-
ated  by  slit-lamp.
Patient  comfort  and  satisfaction  were  evaluated  using  a
isual  analog  scale,10 which  consisted  of  a  10-centimeter-
ong  vertical  line  on  which  each  centimeter  was  marked  with
 horizontal  line  and  numbered  from  bottom  to  top  with
 to  10.  With  a  horizontal  line,  the  subjects  indicated  the
egree  of  comfort  and  satisfaction  achieved  with  their  CLs
t  the  time  of  the  evaluation.  Scores  at  the  lower  end  indi-
ated  extreme  discomfort  or  extreme  dissatisfaction  with
he  CLs;  scores  at  the  upper  end  indicated  extreme  comfort
r  extreme  satisfaction  with  the  CLs.  The  evaluation  was
erformed  by  measuring  in  millimeters  the  space  from  the
ottom  (0)  up  to  the  top  (10).  User  comfort  also  was  ana-
yzed  by  assessing  the  use  of  artiﬁcial  tears  and  the  hours  of
aily  CL  use.
To  analyze  the  CL  anterior  surface  wettability,  the  NIBUT
as  measured  using  TearScope  Plus®  (Keeler,  Windsor,  Berk-
hire,  England,  UK)  by  projecting  its  light  grid  on  the  anterior
L  surface.11 The  subjects  were  instructed  to  blink  three
imes  and  then  keep  their  eyes  open  until  instructed  to  blink
gain.  The  time  in  seconds  that  elapsed  was  recorded  from
hen  the  subject  stopped  blinking  until  the  reﬂected  image
as  deformed,  indicating  tear  ﬁlm  discontinuity.  This  mea-
urement  was  performed  three  times,  and  the  average  of
he  three  measurements  was  recorded.
The  characteristics  of  lens  ﬁtting  (corneal  coverage,
osition,  and  mobility)  were  assessed  according  to  the  stan-
ardized  scale.9 With  a  slit-lamp  it  was  determined  if  the
L  completely  covered  the  cornea.  The  scale  used  to  assess
he  position  ranged  from  0  to  2,  with  0  indicating  a  suitable
nd  centered  position,  1  a  slightly  off-centered  position,  and
 an  excessively  off-centered  position.  Regarding  mobility,
he  scale  used  ranged  from  −2  to  +2,  with  negative  values
ndicating  lack  of  mobility,  0  suitable  mobility,  and  positive
alues  excessive  CL  mobility.
Ocular  surface  health  was  evaluated  at  the  slit-lamp.  All
igns  were  evaluated  on  a  scale  of  0  to  4.9
The  same  experienced  practitioner  examined  all
atients.
dverse  ocular  events  and  severe  adverse  eventsdverse  ocular  events  were  deﬁned  as  reduction  of  at  least
ne  line  of  LogMAR  VA  that  could  not  be  improved  by
he  instillation  of  artiﬁcial  tears,  the  presence  of  corneal
dema,  corneal  inﬁltrates,  corneal  vascularization,  ulcers,
M
0
2
sJ.  Pinto-Fraga  et  al.
ny  corneal  event  resulting  in  permanent  opacity,  or  any
evere  adverse  ophthalmic  event.  A  severe  adverse  event
as  deﬁned  as  any  event  resulting  in  death  or  threat
o  the  life  of  the  subject,  permanent  disability,  required
n  extended  hospital  stay,  involved  cancer  and  congenital
bnormalities,  or  was  the  result  of  an  overdose  (administra-
ion  of  a  dose  higher  than  prescribed).12
tatistical  analysis
tatistical  analyses  were  performed  using  SPSS  18.0  statis-
ical  software  for  Windows  (IBM  Corporation,  Armonk,  NY,
SA)  and  R  version  3.1.0.  The  Shapiro--Wilk  test  was  used  to
heck  the  normality  of  distribution.  p  ≤  0.05  was  considered
tatistically  signiﬁcant.
Quantitative  variables  were  described  using  means  and
tandard  deviations  (SD).  Qualitative  ones  were  summarized
y  percentages.
For  the  primary  safety  and  efﬁcacy  variables,  the  dif-
erences  in  the  percentage  of  subjects  were  evaluated  by
quality  proportion  test  for  paired  groups.  The  same  statis-
ical  method  was  used  to  compare  differences  in  qualitative
ariables  between  control  and  study  groups.  Mean  differ-
nces  for  quantitative  variables  were  checked  by  t-test  for
aired  samples  or  its  non-parametric  alternative  (Wilcoxon
est)  when  the  normality  assumption  could  not  be  assumed.
esults
wenty  subjects  (10  men,  10  women)  were  included  in  the
tudy.  The  average  patient  age  was  27.7  ±  5.6  years  (range,
0--41  years).  All  subjects  met  the  inclusion  criteria,  and  no
ubjects  discontinued  the  study.  All  CL  were  exhibiting  good
t  throughout  the  study.
rimary  safety  variables
ost  subjects  had  ﬂuorescein  staining  values  of  grade  0  or
 maximum  of  grade  1  staining,  except  for  one  subject  with
rade  2  staining  after  15  days  using  the  control  MPDS  and
our  subjects  with  grade  2  staining  after  1  month  using  the
tudy  MPDS  (Fig.  2).  These  differences  were  not  signiﬁcant.
taining  higher  than  grade  2  did  not  occur  during  the  study.
By  assessing  the  percentage  of  subjects  with  corneal
taining  exceeding  grade  0  with  both  MPDSs  and  for  the  three
xaminations,  we  observed  a  higher  percentage  after  15  and
0  days  of  use  of  the  control  MPDS  (50%  in  both  cases)  com-
ared  with  the  test  MPDS  (40%  and  35%,  respectively).  These
ifferences  were  not  signiﬁcant.
No  adverse  events  were  detected  that  were  either
elated  directly  to  the  study  or  control  MPDS  or  the  CL
sed,  and  no  severe  adverse  events  developed  throughout
he  study.
rimary  efﬁcacy  variableost  subjects  had  anterior  surface  deposits  that  were  grade
 or  grade  1  maximally,  except  for  one  subject  with  grade
 deposits  after  1  month  using  the  control  MPDS  and  two
ubjects  with  grade  2  deposits  after  1  month  using  the  study
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Figure  2  Corneal  staining  (primary  safety  variable).  The  data
show the  percentage  of  subjects  with  corneal  ﬂuorescein  stain-
ing on  0,  15,  and  30  days  of  use  of  each  multipurpose  disinfecting
solution  (MPDS)  (study  and  control).  No  staining  higher  than
grade  2  was  seen  throughout  the  study.
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Figure  3  Deposits  on  the  front  surface  of  the  hydrogel  contact
lens (Si-HCL)  (primary  efﬁcacy  variable).  The  data  show  the  per-
centage  of  subjects  with  deposits  on  the  front  surface  of  the
Si-HCL  on  0,  15,  and  30  days  of  use  of  each  multipurpose  disin-
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Figure  4  Subject  comfort  and  satisfaction  with  the  study  and
control  multipurpose  disinfecting  solutions  (MPDSs).  The  data
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efecting  solution  (MPDS)  (study  and  control).  No  staining  higher
than grade  2  occurred  throughout  the  study.
MPDS  (Fig.  3).  Regarding  posterior  surface  deposits,  one  sub-
ject  had  grade  1  deposits  after  1  month  using  the  study
MPDS.  These  differences  were  not  signiﬁcant.
Regarding  the  percentage  of  subjects  with  deposits  on
the  anterior  surface  exceeding  grade  0  with  both  MPDS  and
for  three  examinations,  we  observed  higher  percentages
after  15  and  30  days  of  use  of  the  control  MPDS  (25%  and
52.63%,  respectively)  than  when  using  the  study  MPDS  (10%
and  26.32%,  respectively).  These  differences  were  not  sig-
niﬁcant.Secondary  variables
Subject  comfort  and  satisfaction  were  assessed  after  15  and
30  days  of  use  of  both  MPDSs.  We  observed  higher  average
D
T
bhow the  average  comfort  and  satisfaction  values  of  the  subjects
n days  15  and  30  of  use  of  each  MPDS.  VAS:  visual  analog  scale.
alues  of  comfort  and  satisfaction  for  the  study  MPDS  than
or  the  control  MPDS  throughout  the  study;  however,  these
ifferences  were  not  signiﬁcant  (Fig.  4).
No  subject  reported  the  need  for  artiﬁcial  tears  while
earing  the  CLs  throughout  the  study.  No  differences  were
ound  in  the  hours  or  days  of  CL  use  between  the  MPDSs
hours  of  use/week,  study  MPDS,  50.3  ±  14.93;  control
PDS,  58.16  ±  12.33,  p  =  0.2453).
Higher  NIBUT  values  for  the  control  MPDS  were  observed
fter  15  and  30  days,  with  a  signiﬁcant  (p  =  0.0481)  dif-
erence  at  15  days  and  a  difference  between  the  MPDSs
f  1.62  ±  3.436  seconds.  This  difference  decreased  after  30
ays  and  was  no  longer  signiﬁcant  (0.75  ±  3.54  seconds;
 =  0.3934)  (Fig.  5).
Epithelial  edema,  inﬁltrates,  endothelial  regularity,  fol-
icles  and  anterior  segment  inﬂammation  did  not  change
hroughout  the  study;  all  subjects  had  grade  0  at  all  exami-
ations.
Analysis  of  the  data  obtained  for  bulbar  hyperemia,
imbal  hyperemia,  conjunctival  staining,  papillae,  stromal
dema,  and  corneal  vascularization  showed  no  signiﬁcant
ifferences  in  any  variables  at  any  examinations  between
he  MPDSs  (Table  2).  Nevertheless,  we  observed  trends  in
he  percentage  of  subjects  with  values  exceeding  grade
.  We  observed  fewer  subjects  with  conjunctival  (bulbar)
yperemia  and  staining  higher  than  grade  0  after  15  and
0  days  with  the  study  MPDS  than  with  the  control  MPDS.
egarding  limbal  hyperemia,  the  number  of  subjects  with  a
core  higher  than  grade  0  after  15  days  using  the  study  MPDS
ended  to  increase,  a  trend  that  reversed  after  30  days.  The
rend  toward  an  increase  was  maintained  throughout  the
xaminations  for  the  control  MPDS.iscussion
o  guarantee  the  safety  and  efﬁcacy  of  new  CL  care  solutions
efore  they  become  commercially  available  it  is  necessary
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Table  2  Subjects  with  biomicroscopy  signs  exceeding  grade  0  during  the  study.
Exam  Study  MPDS  Control  MPDS  CI  95%  difference  in  proportions  p  Value
No.  %  No.  %  Lower  Upper
Bulbar  hyperemia 0  d  11  55  10  50  0  49.86  0.8271
15 d  11  55  12  60  0  51.95  0.8347
30 d  12  60  16  80  0  71.11  0.4431
Limbal hyperemia 0  d  6  30  4  20  0  40.68  0.5229
15 d 10  50  7  35  0  54.87  0.4609
30 d 5  25  8  40  0  49.72  0.3971
Conjunctival
staining
0 d 4  20  5  25  0  34.32  0.7382
15 d 7  35  11  55  0  60.64 0.3348
30 d  10  50  12  60  0  55.76  0.6684
Papillae 0 d  4  20  7  35  0  46.83  0.3557
15 d  5  25  8  40  0  49.72  0.3971
30 d 6  30  8  40  0  46.41  0.5903
Stromal edema 0  d 0  0  1  5  0  14.55  0.3049
15 d 0  0  0  0  0  0.00
30 d 0  0  0  0  0  0.00
Corneal
vascularization
0 d 16  80  14  70  0  63.50  0.7141
15 d 15  75  14  70  0  57.73  0.8526
30 d 16  80  16  80  0  55.44  1.0000
MPDS: multipurpose disinfecting solution; CI: conﬁdence interval; Exam: examination; No.: number of subjects who met  the criteria;
%: percentage of subjects who met the criteria. 0 d: day 0, 1 hour o
(examination 3 or 6); 30 d: 30 days of Si-HCL use (examination 4 or 7).
to  perform  a  clinical  trial.  The  main  purpose  of  this  paper  is
to  show  the  results  of  this  clinical  trial  as  is  required  by  the
clinical  trials  regulations.
Aloe  vera  is  well  known  for  its  protection  effect  on  the
epithelium  against  potentially  toxic  substances.13 It  also  has
bactericidal  and  bacteriostatic  properties  and  can  absorb
ultraviolet  light  (UV)  radiation.14 These  properties  are  ideal
as  components  of  a  solution  for  cleaning  and  maintaining
CLs.  Aloe  vera  is  also  a  component  that  is  added  in  different
ophthalmic  formulations.6,13--16
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Figure  5  Anterior  surface  wettability  (NIBUT)  of  the  hydro-
gel contact  lenses  with  both  multipurpose  disinfecting  solutions
(MPDSs)  (study  and  control).  The  data  show  the  average  NIBUT
values  on  days  15  and  30  for  each  MPDS.  The  error  bars  repre-
sent the  standard  deviations.  *  indicates  a  signiﬁcant  (p  <  0.05)
difference  between  the  control  and  study  MPDSs  on  day  15.
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Rf Si-HCL use (examination 2 or 5); 15 d: 15 days of Si-HCL use
The  effect  of  aloe  vera  on  ocular  health  has  been  studied
ecause  of  its  humectant  properties.  Burgalassi  et  al.15 con-
luded  that  ophthalmic  solutions  containing  aloe  vera  were
uitable  to  relieve  dry  eye  symptoms.  Ji  and  Jia16 found
n  an  in  vitro  experiment  that  by  incorporating  aloin  and
olysaccharides  (found  in  aloe  vera  extracts)  into  a  binary
olution,  eyes  were  protected  from  bacterial  infection  and
V  radiation.  This  implies  that  aloe  vera  may  reduce  the
oxic  effect  of  irritants,  thereby  preserving  the  viability  of
orneal  epithelium  cells  against  potential  long-term  toxic-
ty  caused  by  continuous  exposure  of  the  ocular  surface  to
PDSs.  This  effect  is  highest  in  aloe  vera  concentrations
lose  to  1%  (Avizor  S.A.).
This  is  a  crossover  study  in  which  each  subject  used  two
PDSs  (study  and  control).  Each  solution  was  used  for  1
onth  with  the  same  type  of  Si-HCL  (Comﬁlcon  A).  Only
ne  material  was  used  to  avoid  interference  resulting  from
hanges  in  material,  and  this  guaranteed  that  all  differences
ere  related  to  the  MPDSs.  Also,  we  compared  the  aver-
ge  hours  of  weekly  use  of  the  Si-HCLs  with  each  of  the
PDSs  evaluated.  Small  differences  were  seen  that  were
ossibly  related  to  different  habits  of  each  subject.  In  any
ase,  these  differences  were  not  signiﬁcant,  and  this  factor
id  not  affect  the  results  obtained  for  the  others  variables
tudied.
The  new  MPDS  was  not  associated  with  adverse  ocu-
ar  effects  for  any  of  the  safety  variables  included
n  the  ISO  11980:2010  guidance  for  clinical  investiga-
ion  recommendations.9 No  signiﬁcant  differences  were
etected  between  the  study  MPDS  and  the  control  MPDS,
hich  conﬁrmed  the  safety  of  the  new  MPDS.
No  signiﬁcant  differences  were  found  between  both  solu-
ions  in  the  evaluation  of  lens  performance  and  acceptance.
esults  showed  no  interference  in  the  cleaning  ability  of
ion  Safety  and  efﬁcacy  of  a  new  multipurpose  disinfecting  solut
the  MPDS  when  aloe  vera  was  included  in  the  formulation.
The  higher  percentage  of  subjects  with  deposits  exceeding
grade  0  on  the  front  and  back  surfaces  of  the  CLs  after  15
and  30  days  of  use  of  the  control  MPDS  could  have  been
due  to  a  more  beneﬁcial  effect  of  the  study  MPDS.  The
increased  deposits  found  between  days  15  and  30  for  both
solutions  could  have  been  due  to  deposits  over  the  CL  sur-
face  that  increased  with  time  of  wear  and  CL  age.  These
results  agreed  with  previous  reports.17--19
In  the  current  study,  no  differences  in  symptoms  were
found  between  the  two  MPDSs.  Higher  NIBUT  values  for  the
control  MPDS  was  observed  at  15  days,  but  these  differences
may  not  be  considered  clinically  relevant,  and  disappeared
at  30  days  of  use.  No  differences  were  found  in  the  ocular
surface  slit-lamp  evaluation,  indicating  that  both  MPDSs  had
the  same  effect  on  the  ocular  surface.  No  variations  were
found  throughout  the  study  in  the  ﬁtting  characteristics
indicating  that  the  study  MPDS  did  not  alter  CLs  parame-
ters.  No  signiﬁcant  differences  in  comfort  or  satisfaction
were  found  between  the  MPDSs;  however,  the  study  MPDS
obtained  higher  averages  than  the  control  MPDS  for  both
parameters  on  days  15  and  30  of  the  study.
This  study  has  some  limitations  like  the  small  sample  size,
although  according  to  the  statistical  calculation.  Further-
more,  some  items,  like  the  mechanism  of  action  of  aloe  vera
or  the  advantages  of  adding  aloe  vera  in  the  MPDSs,  cannot
be  discussed  using  the  results  of  this  clinical  trial  cause  it
has  been  designed  exclusively  to  study  the  security  and  efﬁ-
ciency  of  the  new  MPDS.  For  that  reason  more  studies  to
prove  the  advantages  of  adding  aloe  vera  in  the  MPDS  are
warranted.
In  conclusion,  the  study  MPDS  is  safe,  has  an  acceptable
physiologic  tolerance,  and  is  efﬁcient  according  to  the  ISO
11980:2010  guidance  for  clinical  investigation.9
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